Baxter International launches the Zosyn (piperacillin and tazobactam) injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria. Ready-to-use products can simplify the preparation process and help improve patient safety by reducing the chance of contamination and avoiding potential dosing errors that may occur when medications are compounded. The Zosyn premix is available in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100 mL presentations. The product uses Baxter’s proprietary Galaxy container technology, a non-PVC and non-DEHP system that enables premixed medications to have a longer shelf life.

• Baxter International, Inc
  For more information, visit pppmag.com/info